IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said a US cancer centre has adopted IB Nimble for its Brain Metastases Program of Excellence.
IB Nimble, developed by IQ-AI's subsidiary Imaging Biometrics, is a mobile and web app that allows secure, remote discussions among medical specialists.
Modern care for brain metastases requires input from various disciplines, often obtained during weekly "tumour boards".
This can delay treatment plans. IB Nimble addresses this by enabling real-time collaboration among specialists, enhancing personalised care.
The identity of the new customer wasn't given, though it was described as a" major East Coast health system".